DrugAgent: Reliable Multi-Agent Integration of Conflicting Biomedical Evidence for Drug-Target Interaction Assessment
arXiv:2408.13378v5 Announce Type: replace Abstract: Workflows in drug-target interaction (DTI) assessment require integrating heterogeneous data from predictive models, curated resources, and observations from experimental literature. This evidence can be incomplete or conflicting. DrugAgent is a large language model (LLM)-based multi-agent system focused on DTI evidence integration that integrates outputs from machine learning, knowledge graph, and retrieval-augmented generation (RAG) agents. DrugAgent converts agent outputs into interpretable representations, then summarizes conflict across
The rapid advancement of large language models and agentic architectures is enabling more sophisticated integrations for scientific discovery, especially where data is heterogeneous and conflicting.
This development indicates a significant step towards automating complex biomedical research workflows, potentially accelerating drug discovery and reducing development costs.
The ability to reliably integrate conflicting biomedical evidence using LLM-based multi-agent systems improves the fidelity and speed of drug-target interaction assessments.
- · Pharmaceutical R&D
- · Biomedical AI developers
- · Patients with unmet medical needs
- · AI agent providers
- · Traditional drug discovery methods
- · Manual data integration specialists
Accelerated drug discovery pipelines and more precise targeting of diseases.
Reduced failure rates in clinical trials due to better pre-clinical validation.
A potential shift in the pharmaceutical industry's competitive landscape, favoring companies that effectively leverage AI agents.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.AI